Production of chimeric mouse-human antibodies with specificity to human tumor antigens
AssigneeXoma Corporation
InventorsMarc D. Better, Arnold H. Horwitz, Randy R. Robinson, Shau-Ping Lei, Changtung P. Chang
Life of this patent
Estimating the term…
Abstract
Gene expression elements and their use in production of chimeric antibodies with human constant regions and murine variable regions, and mouse human chimeric antibodies having specificity to human tumor cells, methods of their production, and their use.
Claims4
An immunoglobulin chimeric heavy chain comprising a human IgG1 constant region and a variable region wherein:
- (a) a chimeric antibody is produced when said heavy chain is combined with a light chain, and said chimeric antibody recognizes a human tumor antigen bound by antibody ING-1;
- (b) the antigen combining site of said chimeric antibody competitively inhibits the immunospecific binding of antibody ING-1 produced by cell line HB9812 as deposited with the ATCC;
- and
- (c) said chimeric antibody mediates an antibody-dependent cellular cytotoxity lysis of target cells at an effector to target ratio of 50:1 when said chimeric antibody concentration is 0.001 .mu.g/ml.
A chimeric antibody comprising two light chains and two heavy chains, each of said heavy chains comprising a human IgG1 constant region and a variable region, and each of said light chains comprising a human light chain constant region and a variable region, wherein:
- (a) said chimeric antibody recognizes a human tumor antigen bound by antibody ING-1;
- (b) the antigen combining site of said chimeric antibody competitively inhibits the immunospecific binding of antibody ING-1 produced by cell line HB9812 as deposited with the ATCC;
- and
- (c) said chimeric antibody mediates an antibody-dependent cellular cytotoxity lysis of target cells at an effector to target ratio of 50:1 when said chimeric antibody concentration is 0.001 .mu.g/ml.
A process for producing a chimeric antibody heavy chain, said process comprising:
- (A) culturing a host capable of expressing said heavy chain, wherein said heavy chain comprises a human IgG1 constant region and a variable region wherein:
- (a) a chimeric antibody is produced when said heavy chain is combined with a light chain, and said chimeric antibody recognizes a human tumor antigen bound by antibody ING-1;
- (b) the antigen combining site of said chimeric antibody competitively inhibits the immunospecific binding of antibody ING-1 produced by cell line HB9812 as deposited with the ATCC;
- and
- (c) said chimeric antibody mediates an antibody-dependent cellular cytotoxity lysis of target cells at an effector to target ratio of 50:1 when said chimeric antibody concentration is 0.001 .mu.g/ml, and
- (B) expressing said heavy chain.
A process for producing a chimeric antibody, said process comprising:
- (A) culturing a host capable of expressing said chimeric antibody, wherein said chimeric antibody comprises two light chains and two heavy chains, each of said heavy chains comprising a human IgG1 constant region and a variable region, and each of said light chains comprising a human light chain constant region and a variable region, wherein:
- (1) said chimeric antibody recognizes a human tumor antigen bound by antibody ING-1;
- (2) the antigen combining site of said chimeric antibody competitively inhibits the immunospecific binding of antibody ING-1 produced by cell line HB9812 as deposited with the ATCC;
- and
- (3) said chimeric antibody mediates an antibody-dependent cellular cytotoxity lysis of target cells at an effector to target ratio of 50:1 when said chimeric antibody concentration is 0.001 .mu.g/ml, and
- (B) expressing said chimeric antibody.
Dependencies are inferred from the claim text.